heat shock protein family E (Hsp10) member 1 pseudogene 9Genealiases: []
Q-omics provides the consensus-scored HSPE1P9 profile across patient tissues and cancer cell-line models. HSPE1P9 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HSPE1P9 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, HSPE1P9 RNA expression shows 9,135 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, BRCA, and HNSC as cancer lineages where HSPE1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPE1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPE1P9 survival associations across molecular data types. HSPE1P9 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPE1P9 RNA expression–survival associations across cancer types. High HSPE1P9 expression shows unfavorable associations in MESO, THYM, LGG, UVM, BRCA and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HSPE1P9 RNA expression.
This table summarizes HSPE1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for HSPE1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPE1P9 shows lower tumor expression in BRCA and higher tumor expression in LUSC, COAD, STAD, LUAD and KICH. The BRCA box plot shows higher HSPE1P9 RNA expression in normal versus tumor tissue (log2 FC = −0.253, t-test p < 0.001).
This table shows molecular features associated with HSPE1P9 in patient tissues and cancer cell lines. In patient samples, HSPE1P9 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
